JP2003512421A - 抗ウィルス複合薬 - Google Patents

抗ウィルス複合薬

Info

Publication number
JP2003512421A
JP2003512421A JP2001532749A JP2001532749A JP2003512421A JP 2003512421 A JP2003512421 A JP 2003512421A JP 2001532749 A JP2001532749 A JP 2001532749A JP 2001532749 A JP2001532749 A JP 2001532749A JP 2003512421 A JP2003512421 A JP 2003512421A
Authority
JP
Japan
Prior art keywords
bms
combination drug
pharmaceutically acceptable
compound
hbv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001532749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003512421A5 (cg-RX-API-DMAC7.html
Inventor
ブラウン,ナサニエル,エー.
コンドレイ,リン,ディー.
グレイ,ダグラス,フラサー
ラビン,マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2003512421A publication Critical patent/JP2003512421A/ja
Publication of JP2003512421A5 publication Critical patent/JP2003512421A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2001532749A 1999-10-29 2000-10-27 抗ウィルス複合薬 Pending JP2003512421A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/429,863 US6432966B2 (en) 1999-10-29 1999-10-29 Antiviral combinations
US09/429,863 1999-10-29
PCT/GB2000/004137 WO2001030329A2 (en) 1999-10-29 2000-10-27 Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction

Publications (2)

Publication Number Publication Date
JP2003512421A true JP2003512421A (ja) 2003-04-02
JP2003512421A5 JP2003512421A5 (cg-RX-API-DMAC7.html) 2007-12-20

Family

ID=23705033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001532749A Pending JP2003512421A (ja) 1999-10-29 2000-10-27 抗ウィルス複合薬

Country Status (10)

Country Link
US (1) US6432966B2 (cg-RX-API-DMAC7.html)
EP (1) EP1225904B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003512421A (cg-RX-API-DMAC7.html)
AR (1) AR026255A1 (cg-RX-API-DMAC7.html)
AT (1) ATE273012T1 (cg-RX-API-DMAC7.html)
AU (1) AU1042701A (cg-RX-API-DMAC7.html)
DE (1) DE60012961T2 (cg-RX-API-DMAC7.html)
ES (1) ES2225245T3 (cg-RX-API-DMAC7.html)
TW (1) TWI282735B (cg-RX-API-DMAC7.html)
WO (1) WO2001030329A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001229775A1 (en) * 2000-02-29 2001-09-12 Bristol-Myers Squibb Company Low dose entecavir formulation and use
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US8168568B1 (en) * 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1抗原決定位胜肽及含此胜肽的疫苗
CN102552210B (zh) * 2012-01-10 2013-12-11 四川海思科制药有限公司 一种恩替卡韦胶囊组合物及其制备方法
KR20170132327A (ko) * 2015-04-07 2017-12-01 스프링 뱅크 파마슈티칼스, 인크. Hbv 감염의 치료를 위한 조성물 및 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04282373A (ja) * 1990-10-18 1992-10-07 E R Squibb & Sons Inc ヒドロキシメチル(メチレンシクロペンチル)プリン類およびピリミジン類
WO1998046241A1 (en) * 1997-04-15 1998-10-22 Advanced Viral Research Corp. A combination therapy for hiv infections
WO1999015175A1 (en) * 1997-09-25 1999-04-01 Cornell Research Foundation, Inc. Method for inhibiting development of liver cancer and increasing survival in chronic hepadnavirus infection
WO1999041268A1 (en) * 1998-02-13 1999-08-19 Medivir Ab Nucleosides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
ATE131730T1 (de) 1991-05-16 1996-01-15 Glaxo Group Ltd Nukleosidanalogen enthaltende antiviren- zubereitungen
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04282373A (ja) * 1990-10-18 1992-10-07 E R Squibb & Sons Inc ヒドロキシメチル(メチレンシクロペンチル)プリン類およびピリミジン類
WO1998046241A1 (en) * 1997-04-15 1998-10-22 Advanced Viral Research Corp. A combination therapy for hiv infections
WO1999015175A1 (en) * 1997-09-25 1999-04-01 Cornell Research Foundation, Inc. Method for inhibiting development of liver cancer and increasing survival in chronic hepadnavirus infection
WO1999041268A1 (en) * 1998-02-13 1999-08-19 Medivir Ab Nucleosides

Also Published As

Publication number Publication date
DE60012961T2 (de) 2005-08-18
DE60012961D1 (de) 2004-09-16
EP1225904A2 (en) 2002-07-31
ATE273012T1 (de) 2004-08-15
ES2225245T3 (es) 2005-03-16
US20020002180A1 (en) 2002-01-03
TWI282735B (en) 2007-06-21
EP1225904B1 (en) 2004-08-11
AR026255A1 (es) 2003-02-05
US6432966B2 (en) 2002-08-13
WO2001030329A2 (en) 2001-05-03
AU1042701A (en) 2001-05-08
WO2001030329A3 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
US20060074094A1 (en) Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
JPH10511682A (ja) ジドブジン、1592u89および3tcまたはftcの相乗的組み合わせ
TW202027751A (zh) 慢性咳嗽治療用醫藥
US20240075033A1 (en) Alk5 inhibitors for treating myelodysplastic syndrome
EP1113802B1 (en) Antiviral combinations of lamivudine and adefovir
EP1225904B1 (en) Combinations of lamivudine and entecavir for treatment of hepatitis b virus infection
US11369612B2 (en) Treatment of RSV with combination product
JP2002526449A (ja) ラミブジンおよびアバカビルを含んでなる抗ウイルス性組合せ製剤
TW201821085A (zh) 用於治療hbv感染的組合物及方法
JPWO1997037657A1 (ja) イミダゾール誘導体を含有する抗hiv組成物
TWI230610B (en) Dosage kits and pharmaceutical compositions for treating HIV infections
HK1035670B (en) Antiviral combinations of lamivudine and adefovir
MXPA01002673A (en) Antiviral combinations
WO2000018383A2 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
WO2000016754A2 (en) Antiviral combinations comprising lamivudine and lobucavir

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110412

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111018